A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Venetoclax (Primary) ; Bendamustine; Rituximab
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; MALT lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 31 Aug 2017 Planned End Date changed from 26 Oct 2017 to 26 Oct 2020.
- 31 Aug 2017 Planned primary completion date changed from 30 Nov 2017 to 26 Oct 2020.
- 20 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 30 Nov 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History